Eye drops remain the dominant treatment for glaucoma and continue to have patient appeal despite innovations in laser and surgery. The glaucoma drops available in New Zealand are either prostaglandin analogues, to increase unconventional uveoscleral outflow, or those that reduce aqueous production. Pilocarpine increases conventional trabecular outflow but is seldom a tolerable long-term option for chronic glaucoma care. Better medications to increase trabecular outflow are being sought because they should reduce fluctuations in intraocular pressure (IOP), and these fluctuations appear to be a risk factor for glaucoma progression.
Sign up to keep reading
Create a free Member account at NZ Optics to read this article and more.
- Read all Member articles
- Full digital magazine archive
- Early access to new articles
